Siemens Healthineers at SNMMI 2018

Expanding precision medicine with molecular imaging

Siemens Healthineers at SNMMI 2018
 
Kontakt

Attend relevant scientific sessions for PET and SPECT at SNMMI 2018.

Scientific Sessions of Interest

 

TimeTitleCategory or Session NameLocation/Room Number
Saturday, June 23
3:25 p.m.-3:35 p.m.PET MRI in patients with multiple myelomaSession 3 - Leukemia/Lymphoma/Myeloma IRoom 111AB
3:35 p.m.-3:45 p.m.Evaluation of two elastic respiratory motion correction techniques in PET/CT imagingSession 2 - Motion Correction (Image Generation)Room 107AB
3:45 p.m.-3:55 p.m.Simultaneous cardiac 18F-FDG1 PET/MR for the assessment of different stages of cardiac impairment in patients with
Anderson-Fabry disease
Session 5 - Cardiovascular Council YIA SymposiumRoom 113B
4:05 p.m.-4:15 p.m.An AI system to determine reconstruction parameters and improve PET image qualitySession 4 - Deep Learning In Molecular Imaging StudiesRoom 113A
4:25 p.m.-4:35 p.m.Data-driven respiratory motion compensation for dynamic cardiac PET imagingSession 2 - Motion Correction (Image Generation)Room 107AB
Sunday, June 24
12:30 p.m.-12:40 p.m.Development and initial results of a prototype brain PET scanner using a time-based digitizer and an FPGA-based real-time coincidence processorSession 12 - Computer & Instrumentation Council YIA SymposiumRoom 113A
12:50 p.m.-1:00 p.m.Deep learning based attenuation correction for whole-body PET studiesSession 12 - Computer & Instrumentation Council YIA SymposiumRoom 113A
3:24 p.m.-3:36 p.m.Evaluation of metabolic tumor volume using different image reconstruction algorithms on 18F-FDG1 PET imageSession 79 - Tech Papers I: Clinical PET -Technologist AbstractsRoom 103C
3:30 p.m.-3:40 p.m.The value of 68Ga-PSMA-617 PET/CT in diagnosis between low-grade and high-grade gliomasSession 18 - Neurooncology - Novel PET ApproachesRoom 114/Nutter Theater
5:21 p.m.-5:33 p.m.Direct comparison of supine and prone SPECT studies in female Veterans Administration undergoing myocardial perfusion imagingSession 80 - Tech Papers II: Cardiovascular Sciences and Pre-clinical Studies TechnologiesRoom 103C
    
Monday, June 25
 1:00 p.m.-1:10 p.m. PET uptake classification in lymphoma and lung cancer using deep learning Session 39 - Deep Learning in Oncology PET Imaging Room 109B
 1:06 p.m.-1:18 p.m. Clinical practicality of quantitative 99mTc-MDP SPECT/CT in patients with breast and prostate osseous metastatic diseaseSession 83 - Tech Papers IV: Instrumentation & Data Analysis
Technologist Abstracts
 Room 103C
 1:10 p.m.-1:20 p.m. Strategy to develop convolutional neural network-based classifier for diagnosis of whole-body FDG1 PET images Session 39 - Deep Learning in Oncology PET Imaging Room 109B
 1:20 p.m.-1:30 p.m. Harmonization of PET image reconstruction parameters on multiple PET/MRI systems Session 35 - Harmonization and standardization for multicenter studies Room 113A
 1:30 p.m.-1:42 p.m. On the quantitative accuracy of xSPECT Quant-based renal uptake determination for internal dosimetry in 177Lu-PSMA radioligand therapy Session 83 - Tech Papers IV: Instrumentation & Data Analysis
Technologist Abstracts
 Room 103C
1:40 p.m.-1:50 p.m.  FDG1 PET imaging of vascular and systemic inflammation in patients with PTSDSession 36 - Advances In Imaging of Atherosclerosis Room 113B
 11:10 a.m.-11:20 a.m. Initial clinical validation of respiratory motion-corrected myocardial viability PET and simultaneous coronary MR angiography Session 28 - Cardiac Metabolism, Viability, and Innervation Room 113B
11:20 a.m.-11:30 a.m. Progress on the EXPLORER project: towards a total body PET scanner for human imaging Session 27 - Systems Room 113A
12:30 p.m.-12:40 p.m.Feasibility of brain PET/CT harmonization - a multicenter, multivendor pilot studySession 35 - Harmonization and standardization for multicenter studiesRoom 113A
 12:40 p.m.-12:50 p.m. Classification and epileptic foci localization of infantile spasms using hybrid PET/MR Session 37 - Pediatrics Room 113C
 12:54 p.m.-1:00 p.m. MR-based attenuation correction and μ map production in PET/MR breast imaging. Session 84 - TS 22: Student Tech Papers II Room 104AB
 2:00 p.m.-4:30 p.m. Hybrid scintillator-semiconductor detector (HSSD) for ultrahigh resolution PET imaging Session 95 - Educational Exhibits Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Non-uniformity images - effect of NaI(Tl) crystal hydration Session 117 - Technologist Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Development of a novel 3D dynamic cardiac phantom simulated human anatomy Session 117 - Technologist Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Dynamic whole-body PET imaging: principles, potentials and applications Session 95 - Educational Exhibits Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Routine production of 18F-PSMA-1007 and first clinical experience in staging of prostate cancer patients Session 105a - Prostate Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. An Investigation of a protocol for PET/CT screening of patients at risk of lung cancer Session 98 - Lung Cancer Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Evaluation of the tumoricidal and pain relief effects of 89Sr on bone metastases of cancer by 18F-Fluoride2 PET/CT, 18F-FDG1 PET/CT, bone scintigraphy/SPECT, and follow-up Session 98 - Lung Cancer Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Multi-parametric PET/MR imaging of anterior prostate cancer based on 11C-Choline uptake and high b-value diffusion Session 105a - Prostate Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. PET MRI: A utilization review perspective Session 95 - Educational Exhibits Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. A pictorial review of 68Ga-DOTATATE PET/MRI for neuroendocrine neoplasm Session 95 - Educational Exhibits Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Dynamic whole-body PET imaging: principles, potentials and applications Session 95 - Educational Exhibits Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Routine production of 18F-PSMA-1007 and first clinical experience in staging of prostate cancer patients Session 105a - Prostate Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. An investigation of a protocol for PET/CT screening of patients at risk of lung cancer Session 98 - Lung Cancer Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Feasibility study of SPECT/CT standard uptake values in differentiating benign and malignant bone lesions Session 117 - Technologist Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Evaluation of normalization methods for the standardized uptake value in bone SPECT/CT Session 117 - Technologist Poster SessionPosters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Establishment of the standard upcate values in SPECT-CT quantification of normal systemic thoracic and lumbar vertebrae Session 117 - Technologist Poster Session Posters located in exhibit hall C
 5:35 p.m.-5:45 p.m. A pilot study to investigate the kinetic parameters of 68Ga-PSMA in primary prostate cancer Session 46 - Technical Advances in Clinical Assessment of Solid Tumors Room 107AB
 5:35 p.m.-6:05 p.m. Reliability of myocardial blood flow estimates in abnormal scans Session 44 - New Developments: Metabolism, Perfusion and Analysis Methods Room 113B
 5:35 p.m. -5:45 p.m. A pilot study to investigate the kinetic parameters of 68Ga-PSMA in primary prostate cancer Session 46 - Technical Advances in Clinical Assessment of Solid Tumors Room 107AB
 5:45 p.m.-5:55 p.m. A new algorithm to harmonize SUV values obtained by different PET/CT scanners Session 46 - Technical Advances in Clinical Assessment of Solid Tumors Room 107AB
   Tuesday, June 26
 1:00 p.m.-1:10 p.m. Accuracy of absolute quantitative SPECT/CT in a multi-vendor and multi-center setting Session 67 - Standardized Imaging Techniques and Performance Room 113A
 1:00 p.m.-1:10 p.m. Bias reduction in 90Y PET with reconstruction that relaxes the nonnegativity constraint Session 68 - Quantitation in Reconstruction (Image Generation) Room 113B
1:00 p.m.-1:10 p.m. Comparison of PET/MRI and PET/CT imaging and dosimetry in patients who have received intra-arterial radioembolization therapy with 90Y microspheres Session 70 - Other Solid Tumors Room 107AB
 10:00 a.m.-10:10 a.m. Higher amyloid deposition in the striatum in very early-onset Alzheimer’s disease: a PIB-PET study Session 57 - Advancing Amyloid Imaging Room 114/Nutter Theater
 10:10 a.m.-10:20 a.m. Direct parametric reconstruction for improved characterization of neurotransmitter release using dynamic PET Session 59 - Kinetic Modeling of Brain PET Studies Room 113A
 10:20 a.m.-10:30 a.m. Quantitative and anatomical assessment of lung perfusion with 99mTc-MAA SPECT/CT in emphysema and lung cancer patients Session 61 - Outcomes/Infectious Disease/Pulmonary II Room 113C
 3:00 p.m.-4:30 p.m. Evaluation two elastic motion correction methodologies on quantification and image quality in PET/CT with patient
data and a phantom study
 Session 116 - Image Generation Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Development of 67Cu quantitative SPECT for clinical dosimetry Session 114 - Data Analysis & Management Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Twin beam dual-energy vs single-energy on a novel PET-dual energy CT: Phantom study and clinical validation. Session 115 - Instrumentation posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Two-injection single-scan rest/stress imaging with 13N-ammonia3: First human studies Session 107 - Cardiovascular Clinical Science Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Statistical analysis of PET radiomic features and metabolomic data: Prediction of triple-negative breast cancer Session 114 - Data Analysis & Management Posters Posters located in exhibit hall C
3:00 p.m.-4:30 p.m.Correction of partial volume effect of cerebral glucose metabolism images measured by PET/MRISession 113 - Neurology & Psychiatry Imaging PostersPosters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Value of PET/MRI in CNS malignancies Session 113 - Neurology & Psychiatry Imaging Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. The impact of volume of interest size on 18F-FDG1 PET radiomic feature robustness: A phantom study Session 114 - Data Analysis & Management Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Brown fat activation, sleep restriction and obesity Session 97 - Endocrine/Neuroendocrine Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Twin beam dual-energy vs single-energy on a novel PET-dual energy CT: Phantom study and clinical validation. Session 115 - Instrumentation posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Two-injection single-scan rest/stress imaging with 13N-ammonia3: First human studies Session 107 - Cardiovascular Clinical Science Poster Session Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Statistical analysis of PET radiomic features and metabolomic data: Prediction of triple-negative breast cancer Session 114 - Data Analysis & Management Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Novel approach for 123I-Ioflupane analysis using xSPECT quantification: Reference values in a normal population Session 113 - Neurology & Psychiatry Imaging Posters Posters located in exhibit hall C
 3:00 p.m.-4:30 p.m. Effect of imaging parameters on multimodal quantitative SPECT with 111In-Octreotide Session 116 - Image Generation Poster Session Posters located in exhibit hall C
3:00 p.m.-4:30 p.m.Extrastriatal 123I-FP-CIT uptake in brain: is it constant?Session 113 - Neurology & Psychiatry Imaging PostersPosters located in exhibit hall C
 3:20 p.m.-3:30 p.m. Impact of attenuation map generation schemes in lesion quantification in prostate cancer patients with PET/MRI Session 76 - PET/MR Quantitation (Image Generation) Room 113B
3:30 p.m.-3:40 p.m.PET-MR attenuaton correction using 3D multi-echo Dixon-based UTE sequenceSession 76 - PET/MR Quantitation (Image Generation)Room 113B
 3:40 p.m.-3:50 p.m. PET-MRI provides incremental value in patients with head and neck cancer Session 74 - Head and Neck Imaging; Diagnostic Performance Room 111AB
 3:40 p.m.-3:50 p.m. Motion-compensated 90Y-PET/MR image reconstruction for enhanced localization and quantification of liver 90Y dose maps Session 76 - PET/MR Quantitation (Image Generation) Room 113B
 3:50 p.m.-4:00 p.m. xSPECT derived absolute and relative SUV: Efficient tools for 123I-Ioflupane analysis Session 73 - Moving Movement Disorder Imaging Forward Room 114/Nutter Theater
  4:20 p.m.-4:30 p.m.  Synthesizing patient-specific transmission images using a multi-channel convolutional neural network framework  Session 76 - PET/MR Quantitation (Image Generation) Room 113B
  

1Fludeoxygluconse F 18 Injection for intravenous use
Indications and usage

Fludeoxyglucose F18 Injection is indicated for positron
emission tomography (PET) imaging in the following settings:

Oncology: For assessment of abnormal glucose metabolism
to assist in the evaluation of malignancy in patients
with known or suspected abnormalities found by other
testing modalities, or in patients with an existing diagnosis
of cancer.

Cardiology: For the identification of left ventricular
myocardium with residual glucose metabolism and
reversible loss of systolic function in patients with coronary
artery disease and left ventricular dysfunction, when used
together with myocardial perfusion imaging.

Neurology: For the identification of regions of abnormal
glucose metabolism associated with foci of epileptic
seizures

DOSAGE AND ADMINISTRATION
Fludeoxyglucose F18 Injection emits radiation. Use
procedures to minimize radiation exposure. Screen for
blood glucose abnormalities.

• In the oncology and neurology settings, instruct patients
to fast for 4 to 6 hours prior to the drug’s injection.
Consider medical therapy and laboratory testing to
assure at least two days of normoglycemia prior to the
drug’s administration.

• In the cardiology setting, administration of glucosecontaining
food or liquids (e.g., 50 to 75 grams) prior to the
drug’s injection facilitates localization of cardiac ischemia.
Aseptically withdraw Fludeoxyglucose F18 Injection from its
container and administer by intravenous injection.

The recommended dose:

• for adults is 5 to 10 mCi (185 to 370 MBq), in all indicated
clinical settings.

• for pediatric patients is 2.6 mCi in the neurology setting.

Initiate imaging within 40 minutes following drug injection;
acquire static emission images 30 to 100 minutes from time
of injection (2).

DOSAGE FORMS AND STRENGTHS
Multi-dose 30mL and 50mL glass vial containing 0.74 to 7.40
GBq/mL (20 to 200 mCi/mL) Fludeoxyglucose F18
Injection and 4.5mg of sodium chloride with 0.1 to 0.5% w/w
ethanol as a stabilizer (approximately 15 to 50 mL volume)
for intravenous administration.

CONTRAINDICATIONS
None

WARNINGS AND PRECAUTIONS
• Radiation risks: use smallest dose necessary for imaging.
• Blood glucose abnormalities: may cause suboptimal
imaging.

ADVERSE REACTIONS
Hypersensitivity reactions have occurred; have emergency
resuscitation equipment and personnel immediately
available.

The full prescribing information is available in the
Siemens Healthineers booth.

2Sodium Fluoride F 18 Injection for Intravenous Use
Indications and usage
Sodium fluoride F 18 injection is a radioactive diagnostic
agent for positron emission tomography (PET) indicated for
imaging bone to define areas of altered osteogenic activity.

Allergic Reactions
As with any injectable drug, allergic reactions and anaphylaxis
may occur. Emergency resuscitation equipment and
personnel should be immediately available.

Cancer Risk
Sodium fluoride F 18 injection may increase the risk of
cancer. Use the smallest dose necessary for imaging
and ensure safe handling to protect the patient and
healthcare worker.

Adverse Reactions
No adverse reactions have been reported based on a review
of the published literature, publicly available reference
sources and adverse drug reaction reporting systems. The
completeness of the sources is not known.

Multiple-dose vial containing 370–7,400 MBq/mL (10–200
mCi/mL) at EOS reference time of no-carrier-added sodium
fluoride F18 in aqueous 0.9% sodium chloride solution.
Sodium Fluoride F 18 Injection is a clear, colorless, sterile,
pyrogen-free and preservative-free solution for intravenous
administration.

The full prescribing information is available in the Siemens
Healthineers booth.
3AMMONIA N 13- ammonia n-13 injection

Indications and usage
Ammonia N 13 Injection is a radioactive diagnostic agent
for Positron Emission Tomography (PET) indicated for
diagnostic PET imaging of the myocardium under rest or
pharmacologic stress conditions to evaluate myocardial
perfusion in patients with suspected or existing coronary
artery disease (1).

CONTRAINDICATIONS
None (4)

WARNINGS AND PRECAUTIONS
Ammonia N 13 Injection may increase the risk of cancer.
Use the smallest dose necessary for imaging and ensure
safe handling to protect the patient and health care
worker (5).

ADVERSE REACTIONS
No adverse reactions have been reported for Ammonia
N 13 Injection based on a review of the published literature,
publicly available reference sources, and adverse drug
reaction reporting system (6).

The full prescribing information is available in the
Siemens Healthineers booth.